Key points
1. Glucocorticoids down-regulate PKM2 and metabolism in CLL cells, impairing access to bioenergetic programs needed to repair cell damage.
2. PPARα and fatty acid oxidation antagonists potentiate the cytotoxic effects of glucocorticoids.
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Introduction
Even with new therapeutic agents, the outcome remains poor for high-risk CLL patients whose tumor cells have lost functional p53 or who relapse shortly after completing firstline therapy with fludarabine, cyclophosphamide, and Rituximab (FCR). 1, 2 High-doses of synthetic glucocorticoids (GCs) such as methylprednisolone or dexamethasone (DEX), with or without monoclonal antibodies such as Ofatumumab, are among the most effective treatments for such patients. 3 However, GC-based regimens are not curative and resistance to GCs is inevitable with continued administration. Knowledge of how GCs exert their therapeutic effects is surprisingly incomplete, considering their long clinical history. 4 A better understanding of the mechanism of action and nature of resistance are needed to improve the efficacy of GC therapy in CLL patients.
GCs are steroid hormones that are made by the adrenal cortex and affect a variety of cell functions. They inhibit glucose metabolism and promote fatty acid oxidation in many tissues during starvation and also have potent immunosuppressive properties. 5 GCs bind to glucocorticoid receptors (GRs), which are members of the nuclear receptor family of ligand-dependent transcription factors. Activation by ligands causes GRs to become phosphorylated and translocate to the nucleus where they bind GC-response elements (GREs) and mediate gene transcription. Ligand-activated GRs transactivate genes such as
IκB that inhibit signaling pathways 6 and also transrepress signaling through direct binding to kinases. 7 GCs cause CLL cells to undergo apoptosis 8 but the processes that lead from GR-phosphorylation to cell death are not fully understood. The studies in this paper were designed to provide more insight into the mechanisms of action of GCs in
CLL.
Materials and methods

Antibodies and reagents. 7-aminoactinomycin D (7-AAD) was obtained from
Pharmingen (San Francisco, CA). Fatty acid free bovine serum albumin, 2-mercaptoethanol (2-ME), Mifepristone, 3,3'-dihexyloxacarbocyanine iodide (DiOC 6 Cell culture. Unless otherwise specified, purified CLL cells were cultured at a concentration of 1 x 10 6 cells/mL in RPMI-1640 medium supplemented with Transferrin and 0.02% AlbuMAX II in 6-or 24-well plates (BD Labware) at 37°C in 5% CO 2 for the times indicated in the figure legends.
Preparation of adipocytes and adipocyte conditioned medium (ACM). OP-9 cells
were maintained in OP-9 propagation medium consisting of MEM-α (Minimum Essential Media α), 20% FBS (Fetal Bovine Serum; BioWhittaker, Walkersville, MD), 100 U/ml penicillin, and 100 mg/ml streptomycin (Wisent USA). The cells were re-plated every 3 days upon growing to confluence. Adipocytes were obtained by the method of Wollins et al. 9 OP-9 cells were grown to confluence in propagation media that was then replaced by stem cell medium (cES), 10 consisting of Advanced-DMEM-F12, 15%
KnockOut™ Serum Replacement, 1% Glutamax-1 (all from Invitrogen), 1% MEM nonessential amino acids (Wisent USA), and 0.1μM 2-ME. Within 3-4 days, more than 90% of OP-9 cells accumulate large lipid droplets visible in a light microscope (Supplementary figure 1C) . To obtain ACM, adipocytes were washed and incubated with fresh cES for 3 days. ACM was collected and heat-inactivated at 60°C for 30 min.
Flow cytometry. Cell viability was measured by first washing in phosphate-buffered saline (PBS) and then staining with 3.5 μL of 7AAD for 10 min. Mitochondrial membrane potential was measured by staining with 0.2 nM of 3,3'-dihexyloxacarbocyanine iodide (DiOC 6 (3)) for 15 min at room temperature followed by 
uncorrected). DSS (0.5mM) was added as an internal reference
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One dimensional (1D) 1 H NMR spectra were collected at 298K with 128 scans using a 90° proton pulse and recycle delay of 2 sec. A total of 32K points were collected over a spectral width of 12.8kHz (16ppm). Metabolites were identified and quantified using the Chenomx 7.1 NMR software suite (Chenomx Inc., Edmonton, AB). Metabolite concentrations are reported as mean values ± standard deviation.
Pyruvate kinase (PK) enzyme activity: Ten million CLL cells were pelleted by centrifugation for 1 min at 3000g at 4°C, washed in 0.9% NaCl, pelleted again and stored in liquid nitrogen. The assay was conducted according to the protocol of Janke et al. 37, 38 ATP produced by PK from ADP and phosphoenolpyruvate (PEP) was fed into the glycerol-3-phosphate (G3P) cycling assay by glycerol kinase. Optimal conditions for measuring G3P levels to indicate maximal PK activity included a cell dilution factor Statistical analysis. Student's t-test and paired t-tests were used to determine p-values.
Best fit lines were determined by least squares regression. Table 1 ). In all cases, GR was phosphorylated by DEX, suggesting this variability was not due to differences in activation of the GR (Fig.1C) . Despite the fact that many DEX-treated cells remained alive, as measured by their ability to exclude the DNA-dye 7AAD, in all cases they became smaller, as measured by the forward scatter parameter of flow cytometry (Fig.1D ).
Dexamethasone decreases mitochondrial membrane potential and intracellular metabolites
Cell size is a reflection of metabolic activity. 13 Accordingly, the decrease in size suggested that metabolism of CLL cells had been impaired by DEX. Cellular metabolism is supported by mitochondria and requires the generation and maintenance of a mitochondrial membrane potential that can be measured by flow cytometry with the cellpermeable, green-fluorescent dye 3,3'-dihexyloxacarbocyanine iodide (DiOC 6 (3)). As early as 4 h after DEX treatment, CLL cells exhibited a significant decrease in mitochondrial membrane potential ( Fig.2A, left ) that was sustained for at least 18 h ( Fig.2A, right) . The decrease in membrane potential could not be attributed to decreased mitochondrial mass (Supplementary Figure 1A) but could be prevented by Mifepristone (see Fig.4F ), suggesting it was a transcriptional effect of DEX. Levels of intracellular metabolites were then measured by nuclear magnetic resonance (NMR) spectroscopy. Consistent with restricted metabolism, a number of metabolites were decreased by DEX. Intracellular glutamate, alanine, and lactate levels were significantly lower (Fig.2B) . Pyruvate, succinate, and glutamine levels were also decreased while acetate was relatively preserved (Fig.2B ). Pyruvate is a product of glycolysis and glutaminolysis that gives rise to lactate and alanine. Glutamate is a product of glutaminolysis that provides Tricarboxylic Acid (TCA) cycle intermediates, such as succinate. 13 Acetate is a product of fatty acid oxidation. 14 Note that these changes in metabolite levels were measured at 18 h, prior to any loss of membrane integrity associated with cell death (Supplementary Figure 1B) and could not be attributed simply to cytotoxicity.
Dexamethasone downregulates pyruvate kinase expression and activity
The decrease in pyruvate, lactate, and alanine levels suggested that genes associated with pyruvate generation were decreased by DEX. Pyruvate kinase muscle isozyme-2 (PKM2)
catalyzes the last step of the glycolytic pathway and transfers a phosphate group from phosphoenolpyruvate to adenosine diphosphate to make pyruvate and ATP. 15 DEXtreated CLL cells down-regulated PKM2 mRNA and protein levels within 4 h (Fig.2C,D) . PK enzyme activity was also decreased by DEX (Fig.2E ).
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Concomitant membrane damage enhances DEX-mediated cytotoxicity
The results above suggested that DEX restricted the ability of CLL cells to generate energy, in part by down-regulating PKM2. To test this idea, CLL cell membranes were disrupted by complement-dependent cytotoxicity, ionophores, or free-fatty acids in the presence and absence of DEX. The rationale for these experiments was that membrane repair requires energy and if DEX-treated CLL cells that suffer concomitant membrane damage cannot generate sufficient energy by increasing glucose metabolism, they may be killed more easily.
Monoclonal antibodies including Rituximab and Ofatumumab, which bind different epitopes on CD20, and Alemtuzumab, which binds CD52, are used in the treatment of CLL 40 and exert their cytotoxic effects in part by depositing complement on the cell surface to form the membrane attack complex. 16 In the absence of complement, Ofatumumab did not change basal killing by DEX in serum-free conditions (Fig.3A) .
However, death of CLL cells from complement damage was increased significantly by DEX (Fig.3A) .
The three antibodies cause different levels of complement damage to cell membranes. Alemtuzumab is the most toxic probably because of the higher levels of CD52 on CLL cells compared to CD20 and possibly because of differences in complement activation as a result of altered mobility of the target molecules after antibody-binding. 40 Ofatumumab is thought to be more toxic than Rituximab because it binds CD20 closer to the cell membrane, leading to more efficient complementdeposition. As a result of these differences in membrane damaging capabilities, DEX would be expected to kill more CLL cells in the presence of Alemtuzumab than with
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Ofatumumab and much more than with Rituximab. As predicted, the combination of Alemtuzumab and DEX killed a greater number of CLL cells than either of the two CD20 antibodies ( Fig.3B and summarized in Fig.3C ). Ofatumumab tended to be more potent than Rituximab but the differences were not statistically significant.
Ionomycin is a calcium ionophore that creates pores in plasma membranes, causing electrochemical gradient disturbances that require significant energy to repair. 17 Consistent with the hypothesis that DEX restricts the metabolic activity needed to repair such damage, ionomycin-mediated cell death was increased significantly by DEX (Fig.3D) .
The serum-free conditions used in these studies would also be expected to damage plasma membranes through detergent-like effects of the fatty acids bound to lipid-rich albumin. 18;19 Removing this source of membrane disruption should then decrease killing of CLL cells by DEX. Consistent with this idea, DEX-mediated cell death was significantly reduced when Albumax was replaced by fatty acid free albumin (Fig.3E) .
Note that the decrease in cell size was still observed (not shown).
DEX increases PPARα expression and activity
The results in Figure 2 suggested that the capacity of CLL cells to generate pyruvate was compromised by DEX. However, the relatively preserved acetate levels (Fig.2B) suggested that genes associated with fatty acid oxidation might be increased in DEXtreated CLL cells. PPARα and PPARδ are nuclear receptors involved in the regulation of fatty acid oxidation. 20;21 DEX up-regulated PPARA and PPARD mRNA and PPARα protein expression (Fig.4A,B,D) . Note that the changes in PPARA mRNA occurred later than the down-regulation of PKM2.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Among the genes regulated by PPARα and PPARδ is pyruvate dehydrogenase kinase 4 (PDK4). PDK4 phosphorylates and inactivates pyruvate dehydrogenase (PDH), preventing pyruvate from being oxidized in mitochondria and promoting fatty acid oxidation. 22 Consistent with the increase in PPARα and PPARδ, PDK4 mRNA expression was also increased by DEX (Fig.4C) .
Adipocyte-derived lipids, lipoproteins and propionic acid reverse the effects of DEX
The decreased expression of PKM2 coupled with increased expression of PPARα, PPARδ, and PDK4 suggested that DEX might cause CLL cells to depend primarily on fatty acid oxidation as a metabolic strategy. Accordingly, they might be able to use fatty acids to generate energy, support mitochondrial activity, and resist the lytic effects of GCs. To investigate this possibility, cultures of DEX-treated cells in serum-free conditions were supplemented with various forms of fatty acid oxidation substrates.
Adipocytes are a major source of fuel for fat-burning tissues and are often found in lymphoid microenvironments where CLL cells reside in vivo. 23 To test whether adipocyte-derived lipids could confer resistance to DEX, CLL cells were co-cultured with OP-9-derived adipocytes. 9 OP-9 is a mesenchymal stem cell line that differentiates rapidly into adipocytes in serum-free conditions 9 (Supplementary Figure 1C) . CLL cells were highly resistant to DEX in the presence of adipocytes, compared to CLL cells in serum-free conditions alone (Fig.5A ).
Soluble factors from adipocytes were mainly responsible for the enhanced survival of DEX-treated CLL cells since conditioned media from OP-9-derived adipocytes also prevented DEX-mediated killing of CLL cells (Fig.5B) . Much of the protective effect survived heat inactivation, suggesting it was due to lipid factors.
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Lipoproteins transport lipids to tissues that use fatty acid oxidation to generate energy. Very-low density lipoproteins (VLDL) and low-density lipoproteins (LDL) increased the survival of DEX-treated cells (Fig.5C ) while high-density lipoproteins (HDL), with lower triglyceride content, had little effect (not shown). Addition of long chain (>12 carbon) fatty acids increased the death of DEX-treated CLL cells, perhaps because of additional detergent-like effects in serum-free culture, as described above (not shown). However, short-chain fatty acids and ketone bodies also failed to increase the survival of DEX-treated CLL cells, despite their capacity to be used as fuel by fatburning tissues without causing membrane damage (not shown). Given that an intact TCA cycle is required to oxidize fatty acids in mitochondria, even-numbered short-chain fatty acids may not be able to be oxidized in DEX-treated cells because of the impaired TCA cycle (Fig.2) . However, odd-numbered fatty acids can be used for both anaplerosis (i.e. to restore depleted TCA cycle intermediates) and as a fuel source. 24 Propionic acid is a short chain 3-carbon fatty acid that is first converted to propionyl coenzyme A (propionyl-CoA) and then to succinyl-CoA, an intermediate of the TCA cycle.
Supplementation with proprionic acid maintained the mitochondrial potential of DEXtreated cells, as measured by DiOC6(3) staining, and increased their viability (Fig.5D,E,F) .
Note that supplementation with glucose or pyruvate did not increase survival of figure 1E) , consistent with a reduced ability to oxidize glucose (Fig.2,4) . Supplementation with glutaminolysis metabolites, including glutamine, glutamate, or alpha-ketoglutarate also failed to rescue DEX-treated CLL cells (Supplementary figure 1D) .
DEX-treated CLL cells (Supplementary
PPARα and fatty acid oxidation mediate GC resistance
The findings that PPARα was upregulated by DEX (Fig.4) and fatty acid oxidation substrates prevented DEX-mediated death (Fig.5) suggested that PPARα and fatty acid oxidation might mediate resistance of CLL cells to GCs. A previously described CLL cell-line model was used to study the effect of increased PPARα-expression on sensitivity to DEX. 21 CD5 + Daudi cells were transfected with human PPARA and a clone was obtained with high PPARα expression (Fig.6A) . 21 DEX activated the GR in both the PPARα-expressing cell line and its empty vector control, as determined by increased phospho-GR levels (Fig.6A ). However the PPARα-expressing cell line was found to be resistant to DEX treatment in comparison to the empty vector control. (Fig.6B) .
Conversely, CLL cells treated with the small molecule PPARα-inhibitor MK886, 21 became more sensitive to DEX (Fig.6C, left upper panel) . In addition, the fatty acid oxidation inhibitor CVT-4325 27 enhanced killing of CLL cells by DEX (Fig.6C, right upper panel). Combination indices for these inhibitors with DEX were less than 1 (Fig.6C, bottom panels) , indicating synergy. 39 Similar results were obtained with two other PPARα-antagonists, GW6471 25 and Compound A 26 (supplementary figure 2) .
PPARα antagonists enhance DEX-mediated clearance of CLL xenografts
The ability of MK886 to improve the therapeutic efficacy of DEX in vivo was then studied in a CLL xenograft model involving transfer of spleen cells from patients who had undergone therapeutic splenectomies into NOD-SCIDγ c null mice along with injections of CLL plasma to support tumor engraftment. 21, 28 Human T and CLL-B cells are found mainly in spleens and peritoneal cavities of tumor-bearing mice by 6 weeks after adoptive transfer. 28 Groups of reconstituted mice were then given 4 daily ip injections of either saline, MK886 at 10 mg/kg (shown previously to partially clear CLL cells 21 ), DEX at 4.6 mg/kg (the dose in the high-dose GC regimen for CLL 3 ) or both MK886 and DEX.
DEX alone did not clear CLL cells from spleens or peritoneal cavities. However, the combination of MK886 and DEX decreased splenic tumor burdens to a greater extent than either agent alone (Fig.6D) , without obvious toxicity. The right and left panels in Fig.6D are the results of two separate experiments using splenocytes from different donors.
Discussion
The findings in this paper suggest: 1. GCs alter metabolic gene expression (Fig.2C, 4) and activity in CLL cells (Fig.2) . 2. GCs prevent tumor cells from accessing bioenergetic programs needed to respond to membrane damage (Fig.3) . 3. GCs increase the dependence of CLL cells on fatty acid oxidation by altering the expression of PPARα and PDK4 (Fig.4) . 4. Use of fatty acids to support metabolism can alleviate restrictions imposed by GCs, constituting a resistance mechanism to GC-mediated cytotoxicity (Fig.5 ). 5. PPARα inhibitors offer a strategy to improve the therapeutic efficacy of GCs (Fig.6 ).
High-dose GCs are used in the treatment of CLL patients, 3 especially those with 17p deletions, but the mechanism of their anti-tumor activity is not clear. GCs have been
shown to change the expression of apoptotic genes and alter signaling processes important for tumor growth by increasing the expression of regulatory molecules such as IκB and phosphatases. [5] [6] [7] [8] However, despite the fact that many of the complications of GC therapy, such as diabetes and hyperlipidemia, are metabolic in nature and a major function of endogenous GCs is to turn off glucose usage and turn on fatty acid oxidation to allow cells to survive an overnight fast, 5 the possibility that the therapeutic activity of GCs in CLL is mediated through metabolism is not widely appreciated. It has been shown that GCs cause leukemia cells to undergo autophagy in some conditions, which is a response to energy deprivation. 29 However, we could find no evidence for autophagy, such as lipidation of LC3, in the serum-free conditions employed here (not shown).
Previous studies have also shown that GCs inhibit glycolysis in acute leukemia cells by restricting glucose uptake and consumption. 30 However, the effect of GCs on pyruvate kinase expression (Fig.2) has not been reported before and may be unique to CLL cells. 36 Regardless, the concept that GCs restrict the metabolic activity of leukemia cells is appealing in that it helps explain why GCs are able to enhance the therapeutic effects of cytotoxic drugs in combination chemotherapy regimens. Moreover, this activity appears to be relatively independent of underlying cytogenetic abnormalities (Fig.1B) , which may explain why HDGCs are among the few treatments with activity against CLL cells harboring 17p deletions. 3 The mechanism(s) whereby GCs down-regulate pyruvate kinase and increase PPARα expression are not clear. The effects appear to be due to transcriptional regulation by GCs because they can be prevented by Mifepristone (Fig.1,5 ). GCs may act directly at the promoters of metabolic genes to positively or negatively regulate their expression and may also regulate the expression of microRNAs (miRs) that control metabolic gene expression. 31 Fatty acid oxidation has been described as a mechanism used by cancer cells to generate energy and survive under conditions of metabolic stress, such as anoikis.
21,32-35
The results reported here are consistent with these observations and suggest that PPARα-mediated fatty acid oxidation also allows CLL cells to survive the metabolic stress imposed by GCs. Concomitant administration of GCs and PPARα-antagonists such as MK886, an agent that has been used before in humans, 21 appears feasible (Fig.6 ) and constitutes a novel strategy to improve the therapeutic efficacy of GC therapy in high-risk CLL patients. 
